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ABSTRACT
Background: Clinicians are increasingly relying on genetic testing to pinpoint definite 
diagnoses. A more general diagnosis of neuropathy or neuromuscular disease like 
myopathy can be narrowed down substantially using genetic testing. Because carrier 
status is of utmost importance in reproductive matters, pathogenic results can 
prognosticate the future course of the illness and help plan ahead for treatment and 
social supports. Given the expense of genetic testing, it is important to assess the 
cost-benefit ratio to determine whether it is worthwhile to collect genetic samples. 
The purpose of the study was to determine the likelihood of obtaining a conclusive 
confirmatory diagnosis through genetic testing (measured as the percent of positive 
results obtained out of all the submitted samples). 
Methods: A single clinician’s record of genetic test outcomes was reviewed spanning 
four years from July 2015 to June 2019 to identify those who had submitted genetic 
samples to Invitae, a commercial lab in California that offers affordable genetic 
testing. All patients were evaluated for complaints of neuromuscular and neuropathic 
nature using the standard of care workup that included a physical exam, lab tests, 
nerve conduction study (NCS), electromyography (EMG), and/or muscle biopsy 
before sending out for genetic testing. The positive, negative, and indeterminate 
genetic diagnoses were tabulated, and the individual disease entities’ prevalence was 
determined. 
results: Of the patients who participated in genetic testing, 96 were diagnosed with 
neuropathic conditions and 59 with neuromuscular conditions. The patients’ health 
records did not have to be mined for results because the clinician’s Invitae account 
contained de-identified requisition numbers linked to their results. The patients in the 
neuromuscular group had twice as many positive results as those in the neuropathic 
group. There were about three times as many normal results in the neuropathic 
group compared to the neuromuscular group. Around half of all test samples showed 
indeterminate results containing variants of unknown significance (VOUS), which were 
not indicative of any pathology and were considered inconclusive. 
conclusion: Based on the study findings, there were 17.7% and 35.6% positive (meaning 
pathogenic) results, respectively, among neuropathic and neuromuscular cases sent 
off for genetic analysis. While 38 out of 155 total cases makes up a small, 24.5% yield 
of abnormal results, genetic studies are still a worthwhile addition to investigating 
neuropathic and neuromuscular cases. 
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INTRODUCTION
Genetic testing has come to the forefront as one 
of the tools a neurologist uses more frequently 
than ever as the next step for patient care after 
a detailed history, careful exam, and appropriate 
workup, including labs and EMG/NCS studies. It 
may even eliminate the need for a muscle, skin, 
or nerve biopsy, depending on the particular 
situation and the clinician’s judgment. This article is 
a retrospective review of all genetic results for next-
generation, sequencing-based gene panel testing 
of patient samples obtained at a neurology clinic 
by one provider to determine the percentage of 
success in reaching a definitive diagnosis (i.e., a 
particular type of neuropathy or myopathy) and 
thus prognosticating future disease course and 
implications for relatives if any. 
METHODS
This study was approved by the Marshall University 
Institutional Review Board (IRB), protocol number 
1427509. The research design consisted of a 
retrospective record review of de-identified genetic 
FIGURE 1. The 102 genes tested for in the Invitae comprehensive neuropathy disorders panel.
FIGURE 2. The 103 genes tested for in the Invitae comprehensive neuromus-
cular disorders panel.
™
MARSHALL JOURNAL OF 
MEDICINE
Expanding Knowledge to Improve Rural Health.
mds.marshall.edu/mjm 
© 2021 Marshall Journal of Medicine
Marshall Journal of Medicine 
Volume 7 Issue 4
results for neurology patients who presented 
to a single practitioner’s outpatient clinic with 
complaints suggestive of a neuromuscular 
problem such as weakness, atrophy, or myalgias, 
versus a neuropathic problem such as numbness, 
paresthesias, or falls. Patients already had a suitable 
workup and gave their consent to submit a genetic 
sample to gather more definitive information 
about their condition and its inheritance pattern 
or to confirm the clinical diagnosis. The Invitae 
neuropathy panel contained 102 genes (figure 1), 
and the neuromuscular panel contained 131 genes 
(figure 2). Inclusion criteria were to include those 
who presented with neuropathic and neuromuscular 
FIGURE 3. Pie chart of Invitae neuropathy panel results.
FIGURE 4. Pie chart of Invitae neuromuscular panel results.
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complaints and who were studied with Invitae’s 
neuropathic or neuromuscular comprehensive gene 
panel. Exclusion criteria were to exclude patients 
who were genetically tested for other conditions due 
to symptoms concerning Parkinson’s, Alzheimer’s, 
and neurofibromatosis. Referrals came from tertiary 
or private offices in the local tri-state area (West 
Virginia, Kentucky, and Ohio), the VA hospital, and 
colleagues in practice. Neurophysiology using 
NCS/EMG studies was employed in the majority of 
cases to distinguish myopathic from neuropathic 
conditions and to grade the severity. Data entry 
consisted of arranging anonymous findings 
consisting of 6 digit requisition numbers in an excel 
spreadsheet and then tabulating the mutation(s) 
involved, carrier status, pathogenicity, or lack thereof, 
FIGURE 5. Comparison of abnormal genetic results.
FIGURE 6. Listing of the number of the particular gene mutations found via the 
Invitae neuropathic panel and the associated disease conditions caused by them. 
AD (autosomal dominant), AR (autosomal recessive).
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along with the presence of inconclusive variants of 
unknown significance (VOUS). 
RESULTS 
One hundred and fifty-five cases were identified as 
eligible for inclusion in the study. Of these, 96 had 
been diagnosed with neuropathy and underwent 
genetic testing with the Invitae comprehensive 
neuropathy disorders panel, and 59 had been 
diagnosed with a neuromuscular condition, such as a 
probable myopathy, and underwent genetic testing 
with the Invitae comprehensive neuromuscular 
disorders panel. Out of 96 neuropathic cases, 17 had 
abnormal, 36 had normal, and 43 had indeterminate 
results. Of the 17 abnormal neuropathic cases, 15 
had an autosomal dominant or X-linked pathogenic 
mutation pattern, and two were carriers of an 
autosomal recessive (AR) pathogenic mutation. Out 
of 59 neuromuscular cases, 21 had abnormal, 8 had 
normal, and 30 had indeterminate results. Of the 21 
abnormal neuromuscular cases, 12 had an autosomal 
dominant pathogenic mutation pattern, and 9 were 
carriers of an autosomal recessive (AR) pathogenic 
mutation. The major disease categories identified are 
described in figure 6 and figure 7. There were twice 
as many positive results in the neuromuscular group 
(35.6%) as in the neuropathic group (17.7%). There 
were about three times as many normal results in the 
neuropathic group (37.5%) as in the neuromuscular 
group (13.6%). The yield of variants of unknown 
significance (VOUS) was roughly half of all the tests 
sent: 44.8% in the neuropathic group and 50.8% in 
the neuromuscular group.
DISCUSSION
The literature does not contain a lot of specific 
data about the prevalence of neuropathic and 
neuromuscular disease in West Virginia. In 1987, 
Benson et al. mentioned an Appalachian region 
kindred with familial amyloid polyneuropathy.1 West 
Virginians may be somewhat under-represented 
in the field of genetic research for various reasons 
such as poverty level, lack of access to higher 
education centers and resources due to financial and 
transportation difficulties, etc., but when looking at 
cancer as a leading cause of death in Appalachia, 
Llanos et al. studied “predictors of willingness to 
participate in biospecimen donation and biobanking 
among Appalachian adults” and found that 97% 
of those who agreed to be tested were willing to 
have their samples sent for genetic studies.2 We 
aimed to expand knowledge about which genetic 
conditions might be uncovered at a single clinician’s 
neurology practice in 4 years at a rural outpatient 
FIGURE 7. Listing of the number of the particular gene mutations found via the Invitae 
neuromuscular panel and the associated disease conditions caused by them. AD (auto-
somal dominant), AR (autosomal recessive).
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neurology clinic in WV. We had 155 patients who 
expressed interest in genetic testing, excluding those 
who agreed to be tested for symptoms other than 
neuropathic or neuromuscular. One limitation of our 
study is that the number of cases sent for genetic 
testing is dependent on the clinical acumen of the 
clinician and the workup leading up to the decision 
to extend genetic testing to patients. While it was 
not feasible to obtain second opinions on all 155 
patient cases, if we did, it might have been useful 
to only send those cases for genetic testing, where 
the other clinician saw a need for it too. Another 
limitation is the small sample size, which may not 
be representative of other regions of WV. We could 
have, perhaps, captured a larger number of cases if 
we invited other neurology practices to participate 
in our study, perhaps even the other university-
based practice in WV that also frequently performs 
genetic testing. The study drew cases from only 
one clinician’s practice, so the case numbers are low 
due to the clinician seeing other general neurology 
cases besides patients voicing neuropathic and 
neuromuscular problems. In a more large-scale 
population study in Northern England, where 
prevalence was calculated per 100,000 inhabitants, 
they were able to confirm the presence of a 
condition by genetic testing in 75.7% of those whom 
they studied.3
Usually, the diagnostic algorithm in a neurology 
clinic involves asking about developmental history, 
specifically, the presence of contractures at birth, 
developmental milestones, ability to keep up 
with peers in races, a pattern of wearing out shoe 
soles, cramps, paresthesias, and any inheritance 
pattern among relatives with similar symptoms. 
The exam may reveal pes cavus, thin calves, sensory 
loss, foot drop, proximal weakness, or scapular 
winging. After sending a combination of labs that 
may include but aren’t limited to A1c, CPK, B12, 
and serum electrophoresis, an NCS/EMG study 
becomes instrumental in pinpointing a need for 
further testing. Genetic testing with next-generation 
sequencing (NGS) may help uncover an explanation 
for a multisystem disease process of neuropathic or 
myopathic disease and help to pinpoint a specific 
neuropathy subtype, of which there are many. While 
whole-exome sequencing is being clinically used, it is 
more costly, has a higher false-positive rate, a longer 
turnaround time, and is more difficult to interpret 
compared to targeted NGS.4 Our study notably 
confirmed that among the cases suspected of having 
a neuropathic condition, as shown in figure 6, there 
were 14 cases of different CMT subtypes, 2 carriers 
of different CMT subtypes, and 1 of Hereditary 
Sensory Autonomic Neuropathy type 1c. Among CMT 
sufferers, the most common was a PMP22 mutation 
(5 cases), then GJB1 mutation (4 cases), then MFN2 
mutation (3 cases). There was 1 case each of MPZ, 
SPTLC2, and LITAF mutation causing CMT. CMT 
is quite prevalent in the general population (1 in 
25,000), so that was not unexpected.5 
In terms of neuromuscular disease, as shown in 
figure 7, our study predominantly confirmed 3 cases 
of paramyotonia congenita, 3 cases of Bethlem 
myopathy, 2 cases of myotonia congenita, 2 cases 
of Laing distal myopathy, 1 case of centronuclear 
myopathy, and 1 case of spinal muscular atrophy. 
There were three carriers of nemaline myopathy 
and 6 carriers of other conditions (limb-girdle 
muscular dystrophy 2H, congenital myasthenic 
syndrome, SMA, myotonia congenita, and muscular 
dystrophy-dystroglycanopathy C14). Curiously, 1 
patient was a carrier of 2 disease conditions (SMA 
and hereditary spastic paraparesis). This shows that 
sometimes, sending a panel containing multiple 
genes is convenient because it can identify several 
mutations at once. However, casting a wide net for 
testing (including genetic testing) is still considered 
controversial, given that Greenberg et al stated 
the viewpoint that “testing should be performed 
as targeted studies, sometimes sequentially, but 
not as wasteful panels of multiple genetic tests 
performed simultaneously.”6 It appears that the 
clinician in our study sent off more test kits for 
neuropathy compared to the number of kits sent 
for neuromuscular testing but received fewer 
confirmations of genetically proven neuropathy, 
which indicates a potential tendency to over-
test patients with a neuropathy presentation. 
This discrepancy could be due to the fact that 
neuropathies have many other potential etiologies 
besides being inherited, such as being caused by 
vitamin deficiencies, systemic illness (diabetes 
and hepatitis C), or by medications (colchicine, 
amiodarone, or certain chemotherapeutics). The ease 
of sending a genetic panel may lead to over-reliance 
on it.
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Genetic testing is important because it can be 
informative about comorbidities that otherwise 
may not be immediately apparent. For example, the 
phenotype of high arches and hammertoes may hint 
at the presence of CMT. While a diagnosis may be 
made clinically, certain CMT subtypes like CMT type 6 
coincide with ocular conditions that may be missed, 
were it not for genetic testing, and optic atrophy can 
be discovered earlier and sufficiently monitored. In 
the case of a patient who is misdiagnosed as CIDP 
based only on soft symptoms and prior NCS studies 
and is refractory to steroids or immunosuppressive 
treatment, genetic testing could potentially help 
reclassify him as CMT 1a. Sometimes, when looking 
for another suspected mutation, a discovery is 
made of a completely different sort, as in our study, 
where one ALS patient was found to be a carrier 
of AR spinal muscular atrophy. Another patient 
was found to be a carrier of 2 AR mutations: spinal 
muscular atrophy and hereditary spastic paraplegia 
11. Normally, familial testing would be offered, but 
the ALS patient was adopted, and the other patient’s 
relative wasn’t interested in getting tested because 
she was unaffected.
One drawback of large panel genetic testing is the 
number of variants of unknown significance (VOUS) 
reported. VOUS are somewhat difficult to explain to 
the patient because they represent polymorphisms 
of uncertain significance. Those with indeterminate 
results may get reclassified in the future, as Invitae 
scans Exome Aggregation Consortium (ExAC) 
databases for other cases of VOUS reported. It is 
easier nowadays than previously to send a genetic 
test, especially on saliva, which can be collected 
in the office. The genetic test allows for arrival 
at a precise diagnosis which otherwise may not 
be established with confidence. A condition like 
muscular dystrophy or inherited neuropathy can be 
narrowed down with genetic testing to a subtype or 
even precisely characterized sooner than could be 
done by clinical exam or biopsy alone. There is often 
not enough time in the clinic to do a full pedigree 
or to examine close relatives in the office. A phone 
consultation via telemedicine with a geneticist 
may prove helpful when the lack of a geneticist 
on site prevents patients from attending genetic 
consultations for post-diagnosis counseling or 
arranging familial testing. 
In terms of clinical application of genetic testing, 
let’s take the example of a hypothetical Duchenne 
muscular dystrophy case. If the clinician has a high 
degree of suspicion upon seeing a young male 
patient with enlarged calves, who is walking on 
tiptoes and has elevated creatinine phosphokinase 
enzyme, a quick genetic test for large deletion/
duplication in the DMD gene or genetic sequencing 
for smaller point mutations can be obtained to 
arrive at the answer faster, rather than waiting to 
do a rather invasive EMG test or a muscle biopsy to 
check if dystrophin protein is absent in the patient’s 
muscle fibers. The earlier the patient is diagnosed, 
the earlier he will have access to supportive care, 
orthotics, assistive devices, and treatments like 
steroids that help preserve respiratory function 
and delay ambulatory decline. His female relatives 
can also be tested to see if they are symptomatic 
carriers, which screens them for heart problems and 
weakness they may develop and gives them access 
to echocardiograms and specialist care, which they 
might not otherwise get. The personal impact of 
genetic testing on someone who, for example, has 
early motor neuron disease but very few symptoms 
and is still functioning may provide early genetic 
confirmation of the condition before progressive 
terminal illness ensues. This would allow some time 
for the patient to visit distant relatives or undertake 
travel before he becomes too ill to travel or would 
allow time for him to move to a better-adapted 
house that may be easier to access and navigate. 
In a case of spinal muscular atrophy (SMA), prior 
knowledge of having an inheritable mutation in 
the family pedigree may facilitate discussion of 
considerations for choosing alternative fertility 
options such as surrogacy or adoption to avoid 
passing on a condition that may have terminal or 
severe consequences to the next generation. Overall, 
genetic testing is highly conducive to streamlining 
and facilitating targeted care and treatment for 
patients.
CONCLUSION
The accumulated results showed the breadth of 
neuromuscular and neuropathic genetic conditions 
present in a typical patient population of a university 
outpatient neurology clinic in rural West Virginia 
(WV) over the course of 4 years during a single 
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clinician’s usual neurology workup supplemented 
by the extra step of genetic testing. Genetic testing 
of this population led to the identification of various 
heritable diseases such as CMT, paramyotonia 
congenita, Bethlem myopathy, congenital myotonia, 
and other rare conditions, the knowledge of which 
benefited the patients and their families. 
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